$146.67
0.18% yesterday
Nasdaq, Sep 24, 10:07 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock price

$146.67
+12.68 9.46% 1M
+31.07 26.88% 6M
+10.17 7.45% YTD
+30.18 25.91% 1Y
+46.10 45.84% 3Y
+47.81 48.36% 5Y
+100.61 218.43% 10Y
+99.93 213.80% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
+0.27 0.18%

Key metrics

Basic
Market capitalization
$14.5b
Enterprise Value
$13.6b
Net debt
positive
Cash
$975.6m
Shares outstanding
99.0m
Valuation (TTM | estimate)
P/E
42.6 | 32.4
P/S
5.8 | 5.1
EV/Sales
5.4 | 4.8
EV/FCF
25.7
P/B
5.4
Financial Health
Equity Ratio
69.6%
Return on Equity
13.2%
ROCE
14.9%
ROIC
12.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.5b | $2.8b
EBITDA
$527.6m | $653.2m
EBIT
$499.1m | $623.7m
Net Income
$348.3m | $448.7m
Free Cash Flow
$528.7m
Growth (TTM | estimate)
Revenue
18.4% | 20.8%
EBITDA
-7.3% | 7.1%
EBIT
-8.4% | 7.0%
Net Income
2.7% | 31.5%
Free Cash Flow
6.9%
Margin (TTM | estimate)
Gross
98.5%
EBITDA
21.0% | 23.0%
EBIT
19.9%
Net
13.9% | 15.8%
Free Cash Flow
21.1%
More
EPS
$3.4
FCF per Share
$5.3
Short interest
5.6%
Employees
2k
Rev per Employee
$1.3m
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

29x Buy
85%
5x Hold
15%

Analyst Opinions

34 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
85%
Hold
15%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,510 2,510
18% 18%
100%
- Direct Costs 38 38
4% 4%
2%
2,472 2,472
19% 19%
98%
- Selling and Administrative Expenses 1,085 1,085
19% 19%
43%
- Research and Development Expense 888 888
41% 41%
35%
528 528
7% 7%
21%
- Depreciation and Amortization 29 29
15% 15%
1%
EBIT (Operating Income) EBIT 499 499
8% 8%
20%
Net Profit 348 348
3% 3%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Neutral
PRNewsWire
2 days ago
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from KINECT-PRO demonstrated substantial symptomatic remission rates at Week 24, even earlier than previous studies have reported.
Neutral
PRNewsWire
3 days ago
SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-1065845).
Neutral
Seeking Alpha
8 days ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 12:40 PM EDT Company Participants Kyle Gano - CEO & Director Sanjay Keswani - Chief Medical Officer Todd Tushla Conference Call Participants Philip Nadeau - TD Cowen, Research Division Presentation Philip Nadeau TD Cowen, Research Division Good afternoon, an...
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kyle Gano
Employees 1,800
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today